Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SER-155

Phase 1Biologic

SSeres Therapeutics, Inc.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Diarrhea

NCT06801067

Clinical

Trials by Indication[1]

Efficacy1 trial

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed·SSeres Therapeutics, Inc.·Phase 1·NCT04995653·60 enrolled

Diarrhea1 trial

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06801067·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SER-155. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SER-155 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SER-155. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seres Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSeres Therapeutics, Inc.

Related News